

## Mylan – Recall of Semglee® (insulin glargine injection)

- On January 19, 2022, the <u>FDA announced</u> a consumer-level recall of one batch of <u>Mylan's</u> (a Viatris company) non-interchangeable <u>Semglee (insulin glargine injection)</u> prefilled pens which are packaged in a labeled carton of five pens because of the potential for the label to be missing on some prefilled pens within a labelled carton for this batch.
- This recall does not pertain to the recently launched interchangeable biosimilars, Semglee (insulin glargine-yfgn) injection, a branded product, or insulin glargine (insulin glargine-yfgn) injection, an unbranded product.
- The recalled batch was distributed between May 2021 and November 2021.

Product Description	NDC	Lot # (Expiration Date)
Semglee (insulin glargine injection), 100 units/mL (U-100), 3 mL prefilled pen	49502-196-75	BF20003118 (8/2022)

- Semglee is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
- A missing label on Semglee prefilled pens, for patients receiving treatment with more than one type of
  insulin (eg, both short and long-acting insulin), could lead to a mix-up of products/strengths, resulting in
  administration of the wrong insulin. Administration of the wrong insulin could result in less optimal
  glycemic control (either high or low blood sugar) which could result in serious complications.
- To date, Mylan has not received any reports of adverse events related to this recall.
- The recalled product can be identified by prefilled pens missing a white label with the product name and dosage information affixed around the pen.
- Patients who have the recalled Semglee should contact their physician or health care provider if they have experienced any problems that may be related to using the recalled Semglee.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- Contact Viatris Customer Relations by phone at 1-800-796-9526 or by email at customer.service@viatris.com for more information about the recall. Contact Stericycle at 1-888-843-0255 for return information.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.